What Genetic Technologies does

Genetic Technologies Limited (NASDAQ: GENE, also referenced as GTG) is a publicly-traded molecular diagnostics company headquartered in Fitzroy, Australia, founded in 1987 and currently employing 101-250 staff. The firm's stated focus is oncology molecular diagnostics, but commercially its revenue-generating platform is the EasyDNA direct-to-consumer DNA testing business, which it acquired from BelHealth in July 2021 for $4 million in cash and stock.

The company operates a direct-to-consumer genomics testing model: customers purchase DNA-based laboratory tests online through EasyDNA-branded websites and distribution agreements covering 40 countries across North America, Asia-Pacific, and Europe. Reported technology is described as "Genomics-based laboratory testing and DNA testing technology" with a single proprietary differentiator around domain specialization in genomic analysis; no proprietary AI/ML, no API platform, and no patent portfolio are disclosed. There is no evidence of in-house technology R&D beyond basic lab operations, and the onboarding of additional test categories appears to rely on extending the EasyDNA product line rather than building new laboratory platforms.

The business model is fundamentally B2C and transactional: revenue is generated through one-time purchases of DNA tests by individual consumers (rather than enterprise subscriptions or licensing), with EasyDNA generating $4.63 million in CY20 revenue as the disclosed baseline. Operations have been funded through repeated small registered direct offerings to institutional investors (approximately $6.56M in January 2021, $5M in February 2023, and $2M in April 2024), with proceeds directed to product commercialization, R&D, sales, and US/Europe expansion. The recurrent dilutive raises at low share prices, combined with limited disclosed operating-financial updates post-2020 and the corporate website (gtgcorporate.com) being listed for sale on a domain marketplace, point to a small, capital-constrained operation heavily dependent on equity markets to sustain itself.

Name

Genetic Technologies

Legal name

Genetic Technologies Limited

Website

https://gtgcorporate.com

Company type

Public

Founded year

1987

Operating status

Operating

Headcount range

101–250 employees

Short description

Genetic Technologies Limited (NASDAQ: GENE) is an Australian publicly-traded molecular diagnostics company that operates direct-to-consumer DNA testing via its wholly-owned EasyDNA subsidiary, serving individual consumers across 40 countries in North America, AsiaPac, and Europe.

Ownership category

akta.pro rank

Product category

Direct-to-consumer genomics testing

NAICS

Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215)

SIC

Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Molecular Diagnostics & Genomics Laboratories (HLAFAMAE)

akta.pro secondary industries

Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics) (HLAAALAD), Molecular & Genetic Testing (PCR/NGS/qPCR) (HLAGADAF), Reference & Esoteric Testing Laboratories (HLAFAMAJ)

Keywords

• Direct-to-consumer DNA testing
• Genomics laboratory services
• Molecular diagnostics oncology
• Personalized genomics
• Genetic health risk tests

Headquarters

HQ city

Fitzroy

HQ country

Australia

HQ region

Oceania

Markets served

GTM type

B2C

Offering type

Services

Cost components

Technology or R&D, Marketing or Sales, Personnel, Operations, Supply Chain

Revenue model

1. Direct-to-Consumer DNA Testing: Revenue generated from genomics-based laboratory tests sold directly to consumers through EasyDNA's online platform and distribution network across 40 countries

Go-to-market motion2 records

Distribution channels1 record

Marketing channels1 record

Core offering

Genetic Technologies provides genomics-based laboratory DNA tests sold primarily through its EasyDNA direct-to-consumer online platform, serving customers across 40 countries in North America, Asia Pacific, and Europe. The company is a molecular diagnostics firm specializing in oncology, leveraging genomics technology to deliver personal health risk assessment and genetic testing products to individual consumers.

Product overview

Genetic Technologies operates as a genomics testing company with a portfolio strategy focused on direct-to-consumer DNA testing. The company expanded its product offerings through the acquisition of EasyDNA in July 2021, acquiring the brand, websites, and distribution rights for US$4 million. EasyDNA represents the company's primary consumer-facing genomics testing brand, offering DNA tests across multiple international markets. The acquisition was designed to establish a platform for growth in the direct-to-consumer genomics testing market segment.

Differentiator

Problem solved

Functional benefit

Products and services

• EasyDNA Direct-to-Consumer DNA Testing An online direct-to-consumer DNA testing service offering genomics-based laboratory tests for health risk assessment and personalized genetic information, operating across 40 countries in North America, Asia Pacific, and Europe.

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

One partnership is on record.

• BelHealthcoreOthers · 19 July 2021Genetic Technologies acquired EasyDNA's brand and distribution rights from BelHealth for $4 million in cash and stock. EasyDNA generated $4.63 million in revenue in CY20 from genomics-based laboratory tests. This acquisition established GTG's platform for growth in direct-to-consumer genomics testing across 40 countries.

Scale indicators7 records

Recent moves5 records

Expansion highlights4 records

Broad incumbents

• Myriad Genetics: Established molecular diagnostics company with deep oncology franchise (BRACAnalysis, myChoice). Comparable to Genetic Technologies' stated oncology molecular diagnostics positioning, though operating at far larger scale and through clinical channels.
• Invitae: Genetic testing company offering hereditary cancer, reproductive health, and pharmacogenomic tests through clinical channels. Comparable to Genetic Technologies on the genomics testing core, with overlapping oncology content.
• Guardant Health: Liquid biopsy and oncology-focused molecular diagnostics company. Comparable to the oncology-diagnostics narrative of Genetic Technologies, though operating at significantly larger scale and in clinical oncology rather than DTC channels.
• Natera: Cell-free DNA testing company with significant oncology (Signatera) and women's health segments. Comparable as a molecular diagnostics company operating in oncology-adjacent testing with established lab infrastructure.

Direct peers

• Ancestry (AncestryDNA): Operates AncestryDNA, the largest DTC genetic genealogy service. Directly comparable to EasyDNA on direct-to-consumer DNA testing model, online distribution, and ancestry/health positioning, with significantly larger database and brand.
• MyHeritage: Offers MyHeritage DNA, a DTC genetic testing service with strong European and international distribution. Closely comparable to EasyDNA on consumer-facing DNA testing across 40+ countries and online funnel.
• 23andMe: Direct-to-consumer DNA testing leader offering ancestry, health risk, and trait reports globally. Most directly comparable to EasyDNA on consumer genomics business model, product category, and target buyer, though at substantially larger scale.

Emerging players

• Nebula Genomics: DTC whole-genome sequencing company with privacy-focused positioning. Comparable to EasyDNA on direct-to-consumer genomics testing model and online distribution, though focused on whole-genome rather than SNP-array products.
• GeneDx: Genomics company focused on rare disease and hereditary cancer testing. Comparable on the molecular diagnostics and genetic testing core with overlapping oncology positioning.
• Color Health: Population-scale genetic testing company offering hereditary cancer and pharmacogenomics tests through DTC and employer channels. Comparable to Genetic Technologies on the molecular diagnostics/genomics testing core, with adjacent oncology positioning.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights4 records

Customer concentration

• LinkedInlinkedin.com/company/genetic-technologies-ltd

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Subsidiaries1 record

Funding overview

Funding rounds6 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Genetic Technologies